JP7674711B1 - ウラシル誘導体を含有する医薬組成物 - Google Patents

ウラシル誘導体を含有する医薬組成物 Download PDF

Info

Publication number
JP7674711B1
JP7674711B1 JP2025509007A JP2025509007A JP7674711B1 JP 7674711 B1 JP7674711 B1 JP 7674711B1 JP 2025509007 A JP2025509007 A JP 2025509007A JP 2025509007 A JP2025509007 A JP 2025509007A JP 7674711 B1 JP7674711 B1 JP 7674711B1
Authority
JP
Japan
Prior art keywords
compound
cov
sars
infection
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2025509007A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2025005306A5 (https=
JPWO2025005306A1 (https=
Inventor
淳 佐藤
啓允 芝山
彰太 上原
佑斗 宇納
啓一朗 平井
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of JPWO2025005306A1 publication Critical patent/JPWO2025005306A1/ja
Priority to JP2025064259A priority Critical patent/JP2025108531A/ja
Application granted granted Critical
Publication of JP7674711B1 publication Critical patent/JP7674711B1/ja
Publication of JPWO2025005306A5 publication Critical patent/JPWO2025005306A5/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2025509007A 2023-10-05 2024-10-04 ウラシル誘導体を含有する医薬組成物 Active JP7674711B1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025064259A JP2025108531A (ja) 2023-10-05 2025-04-09 ウラシル誘導体を含有する医薬組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2023173420 2023-10-05
JP2023173420 2023-10-05
JP2024096866 2024-06-14
JP2024096866 2024-06-14
PCT/JP2024/035560 WO2025005306A1 (ja) 2023-10-05 2024-10-04 ウラシル誘導体を含有する医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025064259A Division JP2025108531A (ja) 2023-10-05 2025-04-09 ウラシル誘導体を含有する医薬組成物

Publications (3)

Publication Number Publication Date
JPWO2025005306A1 JPWO2025005306A1 (https=) 2025-01-02
JP7674711B1 true JP7674711B1 (ja) 2025-05-12
JPWO2025005306A5 JPWO2025005306A5 (https=) 2025-06-04

Family

ID=93938355

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2025509007A Active JP7674711B1 (ja) 2023-10-05 2024-10-04 ウラシル誘導体を含有する医薬組成物
JP2025064259A Pending JP2025108531A (ja) 2023-10-05 2025-04-09 ウラシル誘導体を含有する医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025064259A Pending JP2025108531A (ja) 2023-10-05 2025-04-09 ウラシル誘導体を含有する医薬組成物

Country Status (4)

Country Link
JP (2) JP7674711B1 (https=)
AU (1) AU2024307335A1 (https=)
TW (1) TW202523309A (https=)
WO (1) WO2025005306A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022138988A1 (ja) * 2021-04-14 2022-06-30 塩野義製薬株式会社 ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物
JP2022534186A (ja) * 2020-09-03 2022-07-28 ファイザー・インク ニトリル含有抗ウイルス化合物
JP2023519035A (ja) * 2020-04-05 2023-05-10 ファイザー・インク Ｃｏｖｉｄ－１９を処置するための化合物および方法
WO2023195529A1 (ja) * 2022-04-08 2023-10-12 塩野義製薬株式会社 ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023519035A (ja) * 2020-04-05 2023-05-10 ファイザー・インク Ｃｏｖｉｄ－１９を処置するための化合物および方法
JP2022534186A (ja) * 2020-09-03 2022-07-28 ファイザー・インク ニトリル含有抗ウイルス化合物
WO2022138988A1 (ja) * 2021-04-14 2022-06-30 塩野義製薬株式会社 ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物
WO2022138987A1 (ja) * 2021-04-14 2022-06-30 塩野義製薬株式会社 ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物
WO2023195529A1 (ja) * 2022-04-08 2023-10-12 塩野義製薬株式会社 ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物
WO2023195530A1 (ja) * 2022-04-08 2023-10-12 塩野義製薬株式会社 ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物

Also Published As

Publication number Publication date
TW202523309A (zh) 2025-06-16
WO2025005306A1 (ja) 2025-01-02
AU2024307335A1 (en) 2026-04-16
JPWO2025005306A1 (https=) 2025-01-02
JP2025108531A (ja) 2025-07-23

Similar Documents

Publication Publication Date Title
JP7105430B1 (ja) ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物
JP7466731B2 (ja) トリアジン誘導体を含有する経口投与する製剤
TW202320793A (zh) 含有三嗪衍生物之醫藥組合物
JP7624093B2 (ja) ウイルス増殖阻害活性を有するウラシル誘導体およびそれらを含有する医薬組成物
JP7273455B1 (ja) 新型コロナウイルス感染症治療用医薬
JP7236065B1 (ja) トリアジン誘導体を含有する医薬組成物
JP2024178473A (ja) ウイルス増殖阻害活性を有する二環性含窒素複素環誘導体およびそれらを含有する医薬組成物
WO2023095860A1 (ja) ３ｃｌプロテアーゼ阻害剤及びｃｏｖｉｄ－１９治療用薬剤を組み合わせることを特徴とするｃｏｖｉｄ－１９治療用医薬
JP7261529B1 (ja) ウイルス増殖阻害作用を有するトリアジン誘導体の製造方法
JP7674711B1 (ja) ウラシル誘導体を含有する医薬組成物
CN116782904A (zh) 含有三嗪衍生物的医药组合物
JP7692546B1 (ja) ウラシル誘導体の製造方法
TWI916636B (zh) 新型冠狀病毒感染症治療用醫藥
RU2806042C1 (ru) Триазиновые производные, имеющие ингибиторную активность в отношении репликации вируса, и содержащая их фармацевтическая композиция
HK40081541A (en) Triazine derivative having virus propagation inhibitory effect, and pharmaceutical composition containing same
HK40114521A (en) Pharmaceutical composition containing triazine derivative
HK40081541B (zh) 具有病毒增殖抑制作用的三嗪衍生物及含有其的药物组合物
CN117120057A (zh) 新型冠状病毒传染病治疗用药物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250217

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20250217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250411

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250403

R150 Certificate of patent or registration of utility model

Ref document number: 7674711

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150